(Image Credits: Pixabay) The United States Food and Drug Administration (USFDA) has approved Novo Nordisk ... the first GLP-1 treatment option for people with type 2 diabetes and CKD.

Jan 8 (Reuters) - Danish drugmaker Novo Nordisk (NOVOb.CO), opens new tab ... Novo is trying to develop a weight-loss treatment more powerful than Eli Lilly's (LLY.N), opens new tab rival Zepbound.

Now that Novo Nordisk is the world’s weight-loss juggernaut, will it have to betray its first patients—type 1 diabetics?

The Food and Drug Administration on Tuesday approved Ozempic to reduce the risk of serious complications in people who have ...

A new study highlighted Monday the potential benefits of popular diabetes drugs on a wide range of health issues, including ...

A new study highlighted Monday the potential benefits of popular diabetes drugs on a wide range of health issues including ...

Ozempic and Wegovy do the same thing as GLP-1 would normally do for you — but to enable them to treat diabetes and obesity, ...

Charlotte de la Fuente / Bloomberg / Getty Images Novo Nordisk ... loss treatment than Ozempic that could "still show differentiation" in treating other diseases like type 2 diabetes in future ...

PARIS, France — A new study highlighted Monday the potential benefits of popular diabetes drugs on a wide range of health ... for drugmakers such as Novo Nordisk (Ozempic/Wegovy) and Eli Lilly ...

for the treatment of diabetes and obesity. In 2018, Stephen became senior vice president and global chief medical officer. Prior to joining Novo Nordisk, Stephen was Head of the Oxford Centre for ...